Reuters logo
BRIEF-Mirati Therapeutics provides update on Glesatinib, Sitravatinib clinical trials, pipeline programs
January 5, 2017 / 9:36 PM / 9 months ago

BRIEF-Mirati Therapeutics provides update on Glesatinib, Sitravatinib clinical trials, pipeline programs

Jan 5 (Reuters) - Mirati Therapeutics Inc :

* Mirati Therapeutics provides update on glesatinib and sitravatinib clinical trials and pipeline programs

* Mirati therapeutics inc - early results from trial show clear evidence of tumor responses in NSCLC patients exhibiting ret fusion mutations

* Says expects to provide an additional update on glesatinib program in second half of 2017

* Says expects to provide an additional update on sitravatinib program in Q3 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below